Trial Profile
Morphomics predicts response to ipilimumab in patients with stage IV melanoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Feb 2016
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 05 Feb 2016 New trial record